ES2053896T3 - 4,5-diariltioimidazoles 2-substituidos antihipercolesterolesmicos. - Google Patents

4,5-diariltioimidazoles 2-substituidos antihipercolesterolesmicos.

Info

Publication number
ES2053896T3
ES2053896T3 ES89116858T ES89116858T ES2053896T3 ES 2053896 T3 ES2053896 T3 ES 2053896T3 ES 89116858 T ES89116858 T ES 89116858T ES 89116858 T ES89116858 T ES 89116858T ES 2053896 T3 ES2053896 T3 ES 2053896T3
Authority
ES
Spain
Prior art keywords
carbon atoms
hypercholesterolesmic
diariltioimidazoles
substituted anti
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89116858T
Other languages
English (en)
Inventor
Jeffrey Thomas Billheimer
Peter John Gillies
Wendell Wilkie Wilkerson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Application granted granted Critical
Publication of ES2053896T3 publication Critical patent/ES2053896T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/42—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

DICHA TIOIMIDAZOLA DE FORMULA (I) O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, DONDE R1 Y R2 SON INDEPENDIENTEMENTE H, F, CI, CF3, ALQUILICO DE 1 A 4 ATOMOS DE CARGONO, A ES UN ALQUILENE DE 7 - 20 ATOMOS DE CARBONO O UN RESIDUO ALCOHILENICO CON NO MAS DE DOS ENLACES DOBLES: R3 ES H, CH3 O C2HS; Y N ES 0, 1 O 2 SON PROVISTAS COMO ESTER ETILICO ACIDO 8 - (4,5 - DIFENIL - 1 H IMIDAZOL - 2 - ILTIO) OCTANOICO.
ES89116858T 1988-09-14 1989-09-12 4,5-diariltioimidazoles 2-substituidos antihipercolesterolesmicos. Expired - Lifetime ES2053896T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/244,170 US4900744A (en) 1988-09-14 1988-09-14 Antihypercholesterolemic 4,5-diaryl-2-substituted thioimidazoles

Publications (1)

Publication Number Publication Date
ES2053896T3 true ES2053896T3 (es) 1994-08-01

Family

ID=22921646

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89116858T Expired - Lifetime ES2053896T3 (es) 1988-09-14 1989-09-12 4,5-diariltioimidazoles 2-substituidos antihipercolesterolesmicos.

Country Status (13)

Country Link
US (1) US4900744A (es)
EP (1) EP0359197B1 (es)
JP (1) JPH02174762A (es)
KR (1) KR900004697A (es)
AT (1) ATE83772T1 (es)
AU (1) AU615572B2 (es)
DE (1) DE68904018T2 (es)
DK (1) DK451389A (es)
ES (1) ES2053896T3 (es)
GR (1) GR3006839T3 (es)
IL (1) IL91620A0 (es)
NZ (1) NZ230624A (es)
ZA (1) ZA897022B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290814A (en) * 1988-11-21 1994-03-01 Burroughs Wellcome Co. Anti-atherosclerotic diaryl compounds
JPH05502235A (ja) * 1989-12-12 1993-04-22 ローン―プーラン・サント イミダゾール類
MX9203711A (es) * 1990-01-12 1992-07-01 Rhone Poulenc Rorer Sa Derivados de imidazol y composiciones farmaceuticas que los contienen.
US5011851A (en) * 1990-02-13 1991-04-30 Bristol-Myers Squibb Co. Imidazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
GB9019838D0 (en) * 1990-09-11 1990-10-24 Smith Kline French Lab Compounds
US5179117A (en) * 1991-12-20 1993-01-12 Du Pont Merck Pharmaceutical Company Antihypercholesterolemic 2-substituted imidazoles
US5364875A (en) * 1992-05-11 1994-11-15 The Du Pont Merck Pharmaceutical Company Imidazoles linked to bicyclic heterocyclic groups for the treatment of atherosclerosis
US5310748A (en) * 1992-05-11 1994-05-10 The Du Pont Merck Pharmaceutical Company Imidazoles for the treatment of atherosclerosis
AU5322494A (en) 1992-10-02 1994-04-26 Trustees Of Dartmouth College Bispecific reagents for redirected targeting of low density lipoprotein
US5491152A (en) * 1994-03-23 1996-02-13 The Du Pont Merck Pharmaceutical Company Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US465438A (en) * 1891-12-15 Alcide frangois trouard
US3636003A (en) * 1969-11-17 1972-01-18 Geigy Chem Corp Substituted 2-mercaptoimidazole derivatives
DE2823197A1 (de) * 1978-05-24 1979-11-29 Schering Ag Neue imidazolderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
DE3228271A1 (de) * 1982-07-29 1984-02-02 A. Nattermann & Cie GmbH, 5000 Köln Triphenylimidazolyloxyalkansaeuren und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
DE3323870A1 (de) * 1983-07-02 1985-01-03 A. Nattermann & Cie GmbH, 5000 Köln Neue imidazol-2-ylthioalkansaeuren und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
ZA854550B (en) * 1984-06-18 1986-04-30 Smithkline Beckman Corp Leukotriene antagonists
US4743613A (en) * 1986-04-08 1988-05-10 Smithkline Beckman Corporation Ester prodrugs of dopamine-β-hydroxylase, inhibitors, composition containing them, and method of using them to inhibit dopamine-β-hydroxylase activity
US4734421A (en) * 1986-10-29 1988-03-29 Merck & Co., Inc. Anti-inflammatory substituted 2-benzyl-mercapto-imidazole and pyrimidine derivatives compositions and method of use therefor
US4935438A (en) * 1987-12-29 1990-06-19 Smithkline Beckman Corporation Dopamine-β-hydroxylase inhibitors

Also Published As

Publication number Publication date
NZ230624A (en) 1991-06-25
ATE83772T1 (de) 1993-01-15
ZA897022B (en) 1991-05-29
JPH02174762A (ja) 1990-07-06
IL91620A0 (en) 1990-04-29
DE68904018T2 (de) 1993-04-29
EP0359197B1 (en) 1992-12-23
KR900004697A (ko) 1990-04-12
DK451389D0 (da) 1989-09-13
EP0359197A1 (en) 1990-03-21
US4900744A (en) 1990-02-13
DE68904018D1 (de) 1993-02-04
GR3006839T3 (es) 1993-06-30
DK451389A (da) 1990-03-15
AU4136189A (en) 1990-03-22
AU615572B2 (en) 1991-10-03

Similar Documents

Publication Publication Date Title
LV5748B4 (lv) Mikofenolskabes morfolinoetilesteris ta iegusana un pielietojums
ATE61374T1 (de) Diaminoandrostanderivate.
ES2063452T3 (es) Preparacion y uso de esteres y derivados de n-yodopropargil oxicarbonil aminoacido como agentes antimicrobianos.
ES2053896T3 (es) 4,5-diariltioimidazoles 2-substituidos antihipercolesterolesmicos.
ATE96446T1 (de) Estramustin-ester.
ES2065994T3 (es) Beta-dicetonas substituidas.
ATE140001T1 (de) Isochromanderivate
DK0470275T3 (da) Hudhvidgørende kosmetisk præparat
FI914525A (fi) Foerening, anvaendning och framstaellning.
BR9006025A (pt) Preparacao farmaceutica
ES2059528T3 (es) Compuestos macrolidos.
FI821038L (fi) Morfoliner
ES2139670T3 (es) Derivados de 1-fenilpirrolidona con actividad optica y preparacion de los mismos.
GEP19970660B (en) Macrolide compounds

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 359197

Country of ref document: ES